Teva Confirms Denosumab Is Part Of Its Biosimilar Pipeline
Prolia Biosimilar Asset Is In Phase III Development
Executive Summary
Teva has officially confirmed one of its many biosimilar assets is a rival to Amgen’s Prolia (denosumab) to treat osteoporosis in postmenopausal women. Sandoz, Celltrion and Samsung Bioepis are among those that have previously thrown their hats into the ring.
You may also be interested in...
Gedeon Richter Provides Clues On Key Biosimilar Trial Dates
Hungary’s Gedeon Richter achieved record results in 2020, driven by a near trebling of the firm’s group operating profit and rising sales. Management once again had much to say on the company’s biosimilar ambitions.
Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Alvotech Files Higher-Strength Adalimumab In US And EU
Alvotech has announced the filing of its AVT02 higher-strength adalimumab version of Humira 100mg/ml with both the FDA and the EMA, as well as disclosing expected decision dates. Teva will market the biosimilar in the US and Stada in Europe.